Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-LY: Dabigatran vs Warfarin for Stroke Prevention in Atrial Fibrillation
NCT00262600Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Stroke or Systemic Embolism at 36 months. Started Dec 2005; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00262600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262600.